Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The reactive dicarbonyls, glyoxal and methylglyoxal (MG), increase in diabetes and may participate in the development of diabetic complications. Glyoxal and MG are detoxified by the sequential activities of glyoxalase 1 (GLO1) and glyoxalase 2. To determine the contribution of these dicarbonyls to the etiology of complications, we have genetically manipulated GLO1 levels in apolipoprotein E-null (Apoe(-/-)) mice. Male Apoe(-/-) mice, hemizygous for a human GLO1 transgene (GLO1TGApoe(-/-) mice) or male nontransgenic Apoe(-/-) litter mates were injected with streptozotocin or vehicle and 6 or 20 weeks later, aortic atherosclerosis was quantified. The GLO1 transgene lessened streptozotocin (STZ)-induced increases in immunoreactive hydroimidazolone (MG-H1). Compared to nondiabetic mice, STZ-treated GLO1TGApoe(-/-) and Apoe(-/-) mice had increased serum cholesterol and triglycerides and increased atherosclerosis at both times after diabetes induction. While the increased GLO1 activity in the GLO1TGApoe(-/-) mice failed to protect against diabetic atherosclerosis, it lessened glomerular mesangial expansion, prevented albuminuria and lowered renal levels of dicarbonyls and protein glycation adducts. Aortic atherosclerosis was also quantified in 22-week-old, male normoglycemic Glo1 knockdown mice on an Apoe(-/-) background (Glo1KDApoe(-/-) mice), an age at which Glo1KD mice exhibit albuminuria and renal pathology similar to that of diabetic mice. In spite of ~75% decrease in GLO1 activity and increased aortic MG-H1, the Glo1KDApoe(-/-) mice did not show increased atherosclerosis compared to age-matched Apoe(-/-) mice. Thus, manipulation of GLO1 activity does not affect the development of early aortic atherosclerosis in Apoe(-/-) mice but can dictate the onset of kidney disease independently of blood glucose levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advanced glycation end-products: A review
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001) · Diabetologia · doi:10.1007/s001250051591 · Cited by 2,597 · cited 12×
“Diabetes-induced metabolic derangements including elevated levels of advanced glycation end products (AGEs) are believed to play a causative role in the development of both microvascular and macrovascular diabetic complications (Vlassara and Palace 2002; Yan et al. 2003; Goldin et al. 2006).”
BackgroundInfluentialAdvanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 2×
“Diabetes-induced metabolic derangements including elevated levels of advanced glycation end products (AGEs) are believed to play a causative role in the development of both microvascular and macrovascular diabetic complications (Vlassara and Palace 2002; Yan et al. 2003; Goldin et al. 2006).”
BackgroundEl-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P. L., Roeder, R. G., Cooper, M. E., & Brownlee, M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081188 · Cited by 1,115 · cited 4×
“2010), factors involved in transcriptional regulation (Yao et al. 2007; Ceradini et al. 2008; El-Osta et al. 2008; Thangarajah et al. 2009) and enzymes that provide a defense against oxidative stress (Paget et al.”
BackgroundMethodInfluentialSelf-citationTherapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D., & Zhang, D. D. (2011) · Diabetes · doi:10.2337/db11-0807 · Cited by 507 · cited 1×
“Sulforaphane, an Nrf2 activator, has been shown to attenuate nephropathy in a mouse model of type 1 diabetes (Zheng et al. 2011).”
BackgroundSoro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes · doi:10.2337/db07-1808 · Cited by 407 · cited 1×
“…2007; Ramasamy et al. 2007), it is clear from experiments with RAGE-null mice that RAGE makes an important contribution to both macrovascular (Soro-Paavonen et al. 2008) and microvascular (Myint et al. 2006; Toth et al. 2008; Reiniger et al. 2010) diabetic complications possibly by binding…”
BackgroundArguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts
Ramasamy, R., Yan, S. F., & Schmidt, A. M. (2007) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700008 · Cited by 58 · cited 1×
“While there are differing views on whether AGE-modified proteins are pathophysiological ligands for RAGE (Ahmed and Thornalley 2007; Heizmann 2007; Ramasamy et al. 2007), it is clear from experiments with RAGE-null mice that RAGE makes an important contribution to both macrovascular (Soro-Paavonen…”
Background
Cited by
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Advanced glycation end products in the pathogenesis of chronic kidney disease
Rabbani, N., & Thornalley, P. J. (2018) · Kidney International · doi:10.1016/j.kint.2017.11.034 · Cited by 387
Self-citationThe role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases
Maessen, D. E. M., Stehouwer, C. D. A., & Schalkwijk, C. G. (2015) · Clinical Science · doi:10.1042/cs20140683 · Cited by 334
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics
Rabbani, N., Xue, M., & Thornalley, P. J. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-016-9705-z · Cited by 169
Self-citationGlyoxalase 1 Modulation in Obesity and Diabetes
Rabbani, N., & Thornalley, P. J. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7424 · Cited by 102
“Studies of rodent models of diabetes have found evidence of increased MG in plasma and tissues suffering vascular complications – kidney and peripheral nerve (13,23,29,30,60).”
Self-citation
Metadata
- Authors
- Geoffrion, M., Du, X., Irshad, Z., Vanderhyden, B. C., Courville, K., Sui, G., D'Agati, V. D., Ott-Braschi, S., Rabbani, N., Thornalley, P. J., Brownlee, M., & Milne, R. W.
- Venue
- Physiological Reports
- Publisher
- Wiley
- Published
- 2014-06
- Volume
- 2
- Issue
- 6
- Pages
- e12043
- ISSN
- 2051-817X (ISSN-L)
- OpenAlex
- W2132078235
- Cited by
- 48
- References
- 6
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice. https://app.cochat.ai/papers/10.14814/phy2.12043
- The paper
- Geoffrion, M., Du, X., Irshad, Z., Vanderhyden, B. C., Courville, K., Sui, G., D'Agati, V. D., Ott-Braschi, S., Rabbani, N., Thornalley, P. J., Brownlee, M., & Milne, R. W. (2014). Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice. Physiological Reports. https://doi.org/10.14814/phy2.12043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.